Mabwell-B Shares Surge Over 23% on Promising Cervical Cancer Drug Data Timeline

Stock News04-30

Mabwell-B (02493) saw its shares surge more than 23%, reaching a record high of HK$31.46. At the time of writing, the stock was up 14.36% to HK$29.14, with a turnover of HK$140 million. The company was officially listed on the main board of the Hong Kong Stock Exchange on April 28 and was included in the Stock Connect scheme on its first trading day, becoming the first 18A company to transition from an A-share to an H-share listing. Since its establishment, Mabwell has successfully advanced four products to market approval and has out-licensed four innovative drug candidates. Its core asset, 9MW2821, is the second globally approved Nectin-4 targeted ADC for urothelial carcinoma and the first worldwide to enter pivotal Phase III trials for cervical cancer and triple-negative breast cancer. Interim analyses for three Phase III trials are expected in the second half of this year, with pre-NDA meetings planned with the Center for Drug Evaluation based on the results. Notably, Mabwell announced that the latest clinical results for 9MW2821 in cervical cancer will be presented in both oral and poster sessions at the 2026 ESMO Gynecological Cancers Congress, scheduled for June 17–19, 2026, in Copenhagen, Denmark.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1141606847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 10:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141606847","market":"us","top_or_hot":-1,"title":"Mabwell-B Shares Surge Over 23% on Promising Cervical Cancer Drug Data Timeline","media":"Stock News","content":"<p>Mabwell-B (02493) saw its shares surge more than 23%, reaching a record high of HK$31.46. At the time of writing, the stock was up 14.36% to HK$29.14, with a turnover of HK$140 million. The company was officially listed on the main board of the Hong Kong Stock Exchange on April 28 and was included in the Stock Connect scheme on its first trading day, becoming the first 18A company to transition from an A-share to an H-share listing. Since its establishment, Mabwell has successfully advanced four products to market approval and has out-licensed four innovative drug candidates. Its core asset, 9MW2821, is the second globally approved Nectin-4 targeted ADC for urothelial carcinoma and the first worldwide to enter pivotal Phase III trials for cervical cancer and triple-negative breast cancer. Interim analyses for three Phase III trials are expected in the second half of this year, with pre-NDA meetings planned with the Center for Drug Evaluation based on the results. Notably, Mabwell announced that the latest clinical results for 9MW2821 in cervical cancer will be presented in both oral and poster sessions at the 2026 ESMO Gynecological Cancers Congress, scheduled for June 17–19, 2026, in Copenhagen, Denmark.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell-B Shares Surge Over 23% on Promising Cervical Cancer Drug Data Timeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell-B Shares Surge Over 23% on Promising Cervical Cancer Drug Data Timeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-30 10:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabwell-B (02493) saw its shares surge more than 23%, reaching a record high of HK$31.46. At the time of writing, the stock was up 14.36% to HK$29.14, with a turnover of HK$140 million. The company was officially listed on the main board of the Hong Kong Stock Exchange on April 28 and was included in the Stock Connect scheme on its first trading day, becoming the first 18A company to transition from an A-share to an H-share listing. Since its establishment, Mabwell has successfully advanced four products to market approval and has out-licensed four innovative drug candidates. Its core asset, 9MW2821, is the second globally approved Nectin-4 targeted ADC for urothelial carcinoma and the first worldwide to enter pivotal Phase III trials for cervical cancer and triple-negative breast cancer. Interim analyses for three Phase III trials are expected in the second half of this year, with pre-NDA meetings planned with the Center for Drug Evaluation based on the results. Notably, Mabwell announced that the latest clinical results for 9MW2821 in cervical cancer will be presented in both oral and poster sessions at the 2026 ESMO Gynecological Cancers Congress, scheduled for June 17–19, 2026, in Copenhagen, Denmark.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1141606847","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141606847","pubTimestamp":1777517776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mabwell-B (02493) saw its shares surge more than 23%, reaching a record high of HK$31.46. At the time of writing, the stock was up 14.36% to HK$29.14, with a turnover of HK$140 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","BK4585":"ETF&股票定投概念","02493":"迈威生物-B","BK0239":"医药制造","BK4588":"碎股"},"translate_title":"Mabwell-B股价因宫颈癌药物数据时间表而飙升超过23%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":1,"VXUS":1,"02493":1},"content_text":"Mabwell-B (02493) saw its shares surge more than 23%, reaching a record high of HK$31.46. At the time of writing, the stock was up 14.36% to HK$29.14, with a turnover of HK$140 million. The company was officially listed on the main board of the Hong Kong Stock Exchange on April 28 and was included in the Stock Connect scheme on its first trading day, becoming the first 18A company to transition from an A-share to an H-share listing. Since its establishment, Mabwell has successfully advanced four products to market approval and has out-licensed four innovative drug candidates. Its core asset, 9MW2821, is the second globally approved Nectin-4 targeted ADC for urothelial carcinoma and the first worldwide to enter pivotal Phase III trials for cervical cancer and triple-negative breast cancer. Interim analyses for three Phase III trials are expected in the second half of this year, with pre-NDA meetings planned with the Center for Drug Evaluation based on the results. Notably, Mabwell announced that the latest clinical results for 9MW2821 in cervical cancer will be presented in both oral and poster sessions at the 2026 ESMO Gynecological Cancers Congress, scheduled for June 17–19, 2026, in Copenhagen, Denmark.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141606847","isCrawlerRequest":true}